Abstract
In this paper, drug selection of triptans for the treatment of migraine is performed by means of the SOJA method, which prospectively defines and scores selection criteria. All drugs available in the Netherlands were included in the analysis. The following selection criteria were used (relative weight between brackets): approved indications (40), number of formulations (50), variability of bioavailability (40), drug interactions (85), clinical efficacy (415), side effects (190), acquisition cost (75) and documentation (105). Almotriptan, rizatriptan and sumatriptan show the highest scores, and are the most suitable triptans for formulary inclusion.
Keywords::